Healthcare & Pharmaceuticals

The algorithms that make social media addictive have become powerful mechanisms for drug dealers
Cancer patients in India have reason to be relieved at a high court ruling this week which dismissed a petition by Swiss pharmaceuticals multinational corporation (MNC) Novartis challenging an Indian law which denies patents for minor or trivial improvements to known drugs.
Almost four years after the toppling of Saddam Hussein, Iraq's healthcare system is still a shambles. While most hospitals lack basic supplies, dozens of incomplete clinics and warehoused high-technology equipment remain as a testament to the failed U.S. experiment to reconstruct of Iraq. First in a series of CorpWatch articles.
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.
U.S. imports of sodium thiopental have been banned by a federal judge because of the poor quality of imports. The ruling has struck a serious blow against the death penalty because of the key role the drug plays in lethal injections. Not surprisingly, the state of Texas is furious.
In this pantheon of corporate muscle, no industry wields as much power as the Pharmaceutical Research and Manufacturers Association (PhRMA), a pressure group breathtaking for its deep pockets and aggression, even by the standards of US politics.
As East African countries are about to change national malaria treatment protocols, Medecins Sans Frontieres (MSF) today releases a report in the hope of averting a fatal choice.
With companies eager to tout their "green" credentials to consumers, advertising watchdogs are stepping up efforts to rein in marketers that make false or exaggerated claims.